lorazepam has been researched along with naloxone in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Coassolo, P; Lavé, T; Schneider, G | 1 |
| Strassburg, CP; Tukey, RH | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Greenwald, MK; Stitzer, ML | 1 |
| Bloom, K; Liebl, MG; Mixides, G | 1 |
| Martin, HA | 1 |
| Williams, BN; Yuan, W | 1 |
| Alladio, E; Leardi, R; Pirro, V; Salomone, A; Vincenti, M | 1 |
| Bailey, AM; Baum, RA; Horn, K; Justice, SN; Lewis, T; Morizio, K; Schultz, A; Weant, K | 1 |
| Docci, L; Fowler, S; Krähenbühl, S; Parrott, N; Umehara, K | 1 |
4 review(s) available for lorazepam and naloxone
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Review of Intranasally Administered Medications for Use in the Emergency Department.
Topics: Administration, Intranasal; Anesthetics, Dissociative; Anticonvulsants; Antidotes; Antipsychotic Agents; Dexmedetomidine; Emergency Service, Hospital; Fentanyl; Flumazenil; Haloperidol; Humans; Hydromorphone; Hypnotics and Sedatives; Ketamine; Lorazepam; Midazolam; Naloxone; Narcotic Antagonists; Narcotics | 2017 |
1 trial(s) available for lorazepam and naloxone
| Article | Year |
|---|---|
Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine.
Topics: Adult; Arousal; Brain; Butorphanol; Dose-Response Relationship, Drug; Double-Blind Method; Euphoria; Heroin Dependence; Humans; Hypnotics and Sedatives; Lorazepam; Male; Morphine; Morphine Dependence; Naloxone; Narcotic Antagonists; Opioid-Related Disorders; Receptors, Opioid, kappa; Receptors, Opioid, mu; Substance Withdrawal Syndrome | 1998 |
12 other study(ies) available for lorazepam and naloxone
| Article | Year |
|---|---|
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
Topics: Animals; Biological Availability; Dogs; Humans; Least-Squares Analysis; Liver; Multivariate Analysis; Neural Networks, Computer; Pharmacokinetics; Rats | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Enteral administration of naloxone for treatment of opioid-associated intragastric feeding intolerance.
Topics: Adult; Catheters, Indwelling; Cross Infection; Drug Administration Schedule; Enteral Nutrition; Fatal Outcome; Female; Food Hypersensitivity; Gastric Emptying; Gastrointestinal Motility; Humans; Infusions, Intravenous; Intubation, Gastrointestinal; Lorazepam; Morphine; Naloxone; Narcotics; Pregnancy; Respiratory Distress Syndrome; Respiratory Insufficiency; Time Factors | 2004 |
The possible consequences of combining Lorazepam and buprenorphine/naloxone: a case review.
Topics: Adult; Anti-Anxiety Agents; Buprenorphine; Drug Interactions; Female; Humans; Intubation, Intratracheal; Lorazepam; Naloxone; Narcotic Antagonists; Respiratory Insufficiency | 2011 |
Interactions among benzodiazepine and buprenorphine/naloxone.
Topics: Anti-Anxiety Agents; Buprenorphine; Female; Humans; Lorazepam; Naloxone; Narcotic Antagonists; Respiratory Insufficiency | 2012 |
Chemometric approach to open validation protocols: Prediction of validation parameters in multi-residue ultra-high performance liquid chromatography-tandem mass spectrometry methods.
Topics: Chromatography, High Pressure Liquid; Humans; Hypnotics and Sedatives; Illicit Drugs; Least-Squares Analysis; Limit of Detection; Lorazepam; Naloxone; Narcotic Antagonists; Tandem Mass Spectrometry; Validation Studies as Topic | 2015 |
Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Cell Culture Techniques; Cells, Cultured; Coculture Techniques; Datasets as Topic; Female; Glucuronides; Glucuronosyltransferase; Hepatocytes; Humans; Intestines; Kidney; Liver; Lorazepam; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Models, Biological; Naloxone; Oxazepam; Young Adult; Zidovudine | 2020 |